Transcriptional activation of the MICA gene with an engineered CRISPR-Cas9 system
- PMID: 28322797
- DOI: 10.1016/j.bbrc.2017.03.076
Transcriptional activation of the MICA gene with an engineered CRISPR-Cas9 system
Abstract
Major histocompatibility complex class I polypeptide-related sequence A (MICA) is a prototypical NKG2D ligand. Because immune cells, such as natural killer (NK) cells, recognize virally infected or transformed cells and eliminate them through the interaction between NKG2D receptors on NK cells and NKG2D ligands on pathogenic cells, MICA expression levels are associated with NK cell-mediated immunity. Here, we report that an engineered clustered regularly interspaced short palindromic repeats-Cas9-related complex targeting MICA gene promoter sequences activates transcription of the MICA gene from its endogenous locus. Inhibiting microRNA function, which targets the 3' untranslated region of the MICA gene, enhances this activation. These results demonstrate that the combination of Cas9-based transcriptional activators and simultaneous modulation of microRNA function may be a powerful tool for enhancing MICA protein expression and efficient anti-pathogenic cell immunity.
Keywords: CRISPR; MICA; Transcriptional activation; microRNA.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.FASEB J. 2019 Aug;33(8):9489-9504. doi: 10.1096/fj.201900319R. Epub 2019 May 24. FASEB J. 2019. PMID: 31125275
-
Development of a screening method to identify regulators of MICA shedding.Biochem Biophys Res Commun. 2015 Oct 2;465(4):764-8. doi: 10.1016/j.bbrc.2015.08.081. Epub 2015 Aug 20. Biochem Biophys Res Commun. 2015. PMID: 26299929
-
Diversity and characterisation of polymorphic 3' untranslated region haplotypes of MICA and MICB genes.HLA. 2018 Dec;92(6):392-402. doi: 10.1111/tan.13434. HLA. 2018. PMID: 30471210
-
MHC class I chain-related A: Polymorphism, regulation and therapeutic value in cancer.Biomed Pharmacother. 2018 Jul;103:111-117. doi: 10.1016/j.biopha.2018.03.177. Epub 2018 Apr 7. Biomed Pharmacother. 2018. PMID: 29635123 Review.
-
Battle of the midgets: innate microRNA networking.RNA Biol. 2012 Jun;9(6):792-8. doi: 10.4161/rna.19717. Epub 2012 May 23. RNA Biol. 2012. PMID: 22617882 Review.
Cited by
-
Genome editing of oncogenes with ZFNs and TALENs: caveats in nuclease design.Cancer Cell Int. 2018 Oct 22;18:169. doi: 10.1186/s12935-018-0666-0. eCollection 2018. Cancer Cell Int. 2018. PMID: 30386178 Free PMC article.
-
Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.Front Immunol. 2021 Aug 12;12:712722. doi: 10.3389/fimmu.2021.712722. eCollection 2021. Front Immunol. 2021. PMID: 34456921 Free PMC article.
-
Engineering Metabolism of Chimeric Antigen Receptor (CAR) Cells for Developing Efficient Immunotherapies.Cancers (Basel). 2021 Mar 5;13(5):1123. doi: 10.3390/cancers13051123. Cancers (Basel). 2021. PMID: 33807867 Free PMC article. Review.
-
Genetic reprogramming for NK cell cancer immunotherapy with CRISPR/Cas9.Immunology. 2019 Oct;158(2):63-69. doi: 10.1111/imm.13094. Epub 2019 Aug 14. Immunology. 2019. PMID: 31315144 Free PMC article. Review.
-
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing.Mol Ther Methods Clin Dev. 2021 Apr 24;21:592-606. doi: 10.1016/j.omtm.2021.04.009. eCollection 2021 Jun 11. Mol Ther Methods Clin Dev. 2021. PMID: 34095343 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources